Published in J Neurotrauma on June 01, 2013
Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol (2015) 1.30
Traumatic brain injury, neuroimaging, and neurodegeneration. Front Hum Neurosci (2013) 1.02
Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J Cell Physiol (2015) 0.96
Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol (2016) 0.85
A Review of the Effectiveness of Neuroimaging Modalities for the Detection of Traumatic Brain Injury. J Neurotrauma (2015) 0.83
Polypathology and dementia after brain trauma: Does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy? Exp Neurol (2015) 0.82
Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med (2008) 11.26
Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol (2009) 11.05
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging (2002) 5.78
Astrocyte activation and reactive gliosis. Glia (2005) 5.46
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med (2000) 4.99
The aftermath of boxing. Psychol Med (1973) 4.92
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol (2010) 4.48
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res (2000) 3.84
Brain-derived neurotrophic factor. Growth Factors (2004) 3.66
Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron (2010) 3.49
Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J (1990) 3.36
Neurodegenerative causes of death among retired National Football League players. Neurology (2012) 2.74
Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov (2011) 2.65
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med (2011) 2.60
Association of apolipoprotein E polymorphism with outcome after head injury. Lancet (1997) 2.57
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
The occult aftermath of boxing. J Neurol Neurosurg Psychiatry (1990) 2.41
beta A4 amyloid protein deposition in brain after head trauma. Lancet (1991) 2.41
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol (2003) 2.36
Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat Rev Neurosci (2010) 2.34
Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM R (2011) 2.30
Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 2.24
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21
Sulfated proteoglycans in astroglial barriers inhibit neurite outgrowth in vitro. Exp Neurol (1990) 2.19
Alzheimer's disease: a study of epidemiological aspects. Ann Neurol (1984) 2.17
Voluntary exercise following traumatic brain injury: brain-derived neurotrophic factor upregulation and recovery of function. Neuroscience (2004) 2.15
Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol (2007) 2.15
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol (1999) 1.93
Current concepts: diffuse axonal injury-associated traumatic brain injury. Arch Phys Med Rehabil (2001) 1.92
Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci (2010) 1.82
The molecular pathophysiology of concussive brain injury. Clin Sports Med (2011) 1.82
Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp Neurol (2011) 1.80
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol (2004) 1.63
Corpora amylacea in hippocampal sclerosis. J Neurol Neurosurg Psychiatry (1997) 1.60
Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg (2003) 1.60
Boxing-acute complications and late sequelae: from concussion to dementia. Dtsch Arztebl Int (2010) 1.59
Traumatic brain injury: can the consequences be stopped? CMAJ (2008) 1.58
Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem (1994) 1.56
Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int (2011) 1.56
Epidemiology of Alzheimer's disease. Epidemiol Rev (1992) 1.56
Modulating astrogliosis after neurotrauma. J Neurosci Res (2001) 1.56
Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry (2002) 1.50
Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology (1986) 1.48
Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol (2001) 1.48
Neurochemical aftermath of amateur boxing. Arch Neurol (2006) 1.47
A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol (2008) 1.46
Α-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta (2011) 1.43
Ultrastructural studies of diffuse axonal injury in humans. J Neurotrauma (1994) 1.43
Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol (1991) 1.43
Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann Neurol (1993) 1.42
Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol (2007) 1.38
Brain damage in modern boxers. JAMA (1984) 1.35
Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging (2006) 1.34
Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol (1999) 1.33
Astroglia in CNS injury. Glia (1991) 1.32
Chronic traumatic brain injury associated with boxing. Semin Neurol (2000) 1.32
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol (2011) 1.32
Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma (2008) 1.30
Head injury and dementia. Curr Opin Neurol (2004) 1.28
Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res (2004) 1.28
Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res (2006) 1.26
Inhibition of neurite outgrowth on astroglial scars in vitro. J Neurosci (1990) 1.26
Partial interruption of axonal transport due to microtubule breakage accounts for the formation of periodic varicosities after traumatic axonal injury. Exp Neurol (2011) 1.26
Neurobiological consequences of traumatic brain injury. Dialogues Clin Neurosci (2011) 1.25
CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One (2012) 1.25
Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol (2006) 1.20
Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma (2010) 1.19
Inhibition of angiogenesis by Abeta peptides. Angiogenesis (2004) 1.19
Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg (2009) 1.17
Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res (2003) 1.16
A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Neuroreport (1997) 1.15
Markers of axonal injury in post mortem human brain. Acta Neuropathol (1994) 1.14
Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry (2003) 1.13
Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Acta Neurochir Suppl (1996) 1.13
Post-traumatic Alzheimer's disease: preponderance of a single plaque type. Neuropathol Appl Neurobiol (1991) 1.13
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans (2011) 1.12
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
Review: Contact sport-related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates. Neuropathol Appl Neurobiol (2011) 1.07
Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol (2010) 1.07
Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res (2008) 1.05
Traumatic brain injuries: structural changes. J Neurol Sci (1991) 1.01
Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol (2004) 1.01
Neural stem cells over-expressing brain-derived neurotrophic factor (BDNF) stimulate synaptic protein expression and promote functional recovery following transplantation in rat model of traumatic brain injury. Neurochem Res (2011) 1.01
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis (2005) 1.01
Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation. Brain Pathol (1994) 1.00
Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem (2009) 1.00
CNS glial scar tissue: a source of molecules which inhibit central neurite outgrowth. Prog Brain Res (1992) 1.00
Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS One (2012) 0.99
Traumatic brain injury hospitalizations of U.S. army soldiers deployed to Afghanistan and Iraq. Am J Prev Med (2010) 0.98
beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol (2000) 0.98
Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res (2010) 0.98
Is there a genetic basis for the deposition of beta-amyloid after fatal head injury? Cell Mol Neurobiol (1999) 0.96
Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics (2003) 0.96
A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. J Neurotrauma (2009) 0.94
Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol Dis (2004) 0.94
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Defining mild cognitive impairment in Parkinson's disease. Mov Disord (2007) 3.92
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (2008) 2.58
Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol (2003) 2.36
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord (2014) 2.17
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet (2010) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol (2005) 1.98
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med (2003) 1.79
Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol (2013) 1.77
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Alzheimer's disease a century later. J Clin Psychiatry (2006) 1.74
Relationship of cognitive measures and gray and white matter in Alzheimer's disease. J Alzheimers Dis (2006) 1.74
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol (2010) 1.69
Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (2006) 1.64
Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res (2006) 1.56
Brain biochemistry in autopsied patients with essential tremor. Mov Disord (2011) 1.56
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol (2007) 1.53
Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry (2002) 1.50
An association with great implications: vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 1.50
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry (2005) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank (2010) 1.46
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord (2010) 1.42
Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res (2008) 1.38
Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia (2004) 1.35
Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res (2004) 1.28
The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord (2011) 1.28
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion (2006) 1.25
Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2005) 1.24
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res (2005) 1.22
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis (2007) 1.20
Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology (2014) 1.19
Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol (2012) 1.18
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry (2002) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol (2012) 1.14
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res (2005) 1.13
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp Cell Res (2006) 1.13
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol (2006) 1.11
Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One (2012) 1.09